Stocktoria
Onconetix, Inc. ONCO
Onconetix, Inc. (ONCO) earns a Piotroski F-score of 4/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $815,371 at a -1721.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ONCO | Onconetix, Inc. | 4/9 | — | — | — |
| HYPD | HYPERION DEFI, INC. | 5/9 | -16.62 | — | — |
| MCRB | Seres Therapeutics, Inc. | 5/9 | — | 12 | — |
| RLYB | Rallybio Corp | 3/9 | 0.76 | — | — |
| BGMS | Bio Green Med Solution, Inc. | 3/9 | — | — | — |
| RFL | Rafael Holdings, Inc. | 3/9 | 0.8 | — | — |
| LEXX | Lexaria Bioscience Corp. | 4/9 | — | — | — |
About Onconetix, Inc.
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.
FAQ
Is ONCO financially healthy?
Onconetix, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does ONCO pay a dividend?
No, Onconetix, Inc. does not currently pay a dividend.
How profitable is ONCO?
In FY2025, Onconetix, Inc. had a net margin of -1721.0% and a return on equity of -89.0%.
Is ONCO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Onconetix, Inc.: a Piotroski F-score of 4/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.